PriceTargets.com logo

DexCom - DXCM Stock Price Target and Predictions

  • Consensus Rating: Moderate Buy
  • Consensus Price Target: $98.11
  • Forecasted Upside: 14.55%
  • Number of Analysts: 20
  • Breakdown:
  • 0 Sell Ratings
  • 4 Hold Ratings
  • 13 Buy Ratings
  • 3 Strong Buy Ratings
$85.65 As of 05/21/2025 12:30 PM ET
▼ -1.689 (-1.93%)

This chart shows the closing price for DXCM by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New DexCom Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for DXCM and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for DXCM

Analyst Price Target is $98.11
▲ +14.55% Upside Potential
This price target is based on 20 analysts offering 12 month price targets for DexCom in the last 3 months. The average price target is $98.11, with a high forecast of $120.00 and a low forecast of $82.00. The average price target represents a 14.55% upside from the last price of $85.65.

This chart shows the closing price for DXCM for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart




Current Consensus is Moderate Buy

The current consensus among 20 polled investment analysts is to moderate buy stock in DexCom. This Moderate Buy consensus rating has held steady for over two years.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 1 strong buy ratings
  • 12 buy ratings
  • 2 hold ratings
  • 0 sell ratings
Ratings as of
11/27/2023
  • 1 strong buy ratings
  • 10 buy ratings
  • 2 hold ratings
  • 0 sell ratings
Ratings as of
2/25/2024
  • 1 strong buy ratings
  • 11 buy ratings
  • 2 hold ratings
  • 0 sell ratings
Ratings as of
5/25/2024
  • 1 strong buy ratings
  • 11 buy ratings
  • 6 hold ratings
  • 0 sell ratings
Ratings as of
8/23/2024
  • 1 strong buy ratings
  • 11 buy ratings
  • 6 hold ratings
  • 0 sell ratings
Ratings as of
11/21/2024
  • 2 strong buy ratings
  • 13 buy ratings
  • 3 hold ratings
  • 0 sell ratings
Ratings as of
2/19/2025
  • 3 strong buy ratings
  • 13 buy ratings
  • 4 hold ratings
  • 0 sell ratings
Ratings as of
4/20/2025
  • 3 strong buy ratings
  • 13 buy ratings
  • 4 hold ratings
  • 0 sell ratings
Ratings as of
5/20/2025

Latest Recommendations

  • 3 strong buy ratings
  • 13 buy ratings
  • 4 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetDetails
5/5/2025BarclaysBoost TargetEqual Weight ➝ Equal Weight$90.00 ➝ $93.00
5/2/2025Piper SandlerLower TargetOverweight ➝ Overweight$100.00 ➝ $90.00
5/2/2025Canaccord Genuity GroupBoost TargetBuy ➝ Buy$103.00 ➝ $106.00
5/2/2025Robert W. BairdLower TargetOutperform ➝ Outperform$115.00 ➝ $105.00
4/10/2025MizuhoInitiated CoverageOutperform$85.00
4/9/2025MizuhoUpgradeStrong-Buy
3/21/2025Cfra ResearchUpgradeHold
3/8/2025Wells Fargo & CompanyReiterated RatingOverweight ➝ Overweight
3/4/2025CitigroupBoost TargetBuy ➝ Buy$101.00 ➝ $104.00
2/14/2025Morgan StanleyBoost TargetEqual Weight ➝ Equal Weight$75.00 ➝ $82.00
2/14/2025Canaccord Genuity GroupBoost TargetBuy ➝ Buy$99.00 ➝ $103.00
2/3/2025Redburn AtlanticUpgradeNeutral ➝ Buy$85.00 ➝ $115.00
1/16/2025Baird R WUpgradeHold ➝ Strong-Buy
1/16/2025Robert W. BairdUpgradeNeutral ➝ Outperform$86.00 ➝ $104.00
12/11/2024CitigroupBoost TargetBuy ➝ Buy$85.00 ➝ $91.00
12/11/2024Wells Fargo & CompanyBoost TargetOverweight ➝ Overweight$90.00 ➝ $94.00
12/9/2024Canaccord Genuity GroupBoost TargetBuy ➝ Buy$89.00 ➝ $99.00
10/25/2024Sanford C. BernsteinBoost TargetOutperform ➝ Outperform$82.00 ➝ $86.00
10/25/2024Royal Bank of CanadaLower TargetOutperform ➝ Outperform$120.00 ➝ $115.00
10/25/2024Raymond JamesLower TargetStrong-Buy ➝ Strong-Buy$115.00 ➝ $99.00
10/25/2024OppenheimerLower TargetOutperform ➝ Outperform$115.00 ➝ $105.00
10/25/2024JPMorgan Chase & Co.Boost TargetNeutral ➝ Neutral$75.00 ➝ $85.00
10/25/2024Leerink PartnersLower TargetOutperform ➝ Outperform$90.00 ➝ $87.00
10/25/2024Wells Fargo & CompanyBoost TargetOverweight ➝ Overweight$80.00 ➝ $90.00
10/8/2024Royal Bank of CanadaLower TargetOutperform ➝ Outperform$130.00 ➝ $120.00
8/26/2024Piper SandlerReiterated RatingOverweight ➝ Overweight$90.00 ➝ $90.00
8/23/2024Stifel NicolausBoost TargetBuy ➝ Buy$90.00 ➝ $100.00
8/5/2024Robert W. BairdBoost TargetNeutral ➝ Neutral$80.00 ➝ $82.00
7/29/2024BarclaysLower TargetEqual Weight ➝ Equal Weight$138.00 ➝ $113.00
7/26/2024Baird R WDowngradeStrong-Buy ➝ Hold
7/26/2024BTIG ResearchLower TargetBuy ➝ Buy$156.00 ➝ $120.00
7/26/2024Morgan StanleyLower TargetEqual Weight ➝ Equal Weight$120.00 ➝ $75.00
7/26/2024UBS GroupLower TargetBuy ➝ Buy$163.00 ➝ $95.00
7/26/2024OppenheimerLower TargetOutperform ➝ Outperform$150.00 ➝ $115.00
7/26/2024Stifel NicolausLower TargetBuy ➝ Buy$132.00 ➝ $90.00
7/26/2024Royal Bank of CanadaLower TargetOutperform ➝ Outperform$165.00 ➝ $145.00
7/26/2024Piper SandlerLower TargetOverweight ➝ Overweight$150.00 ➝ $90.00
7/26/2024Wells Fargo & CompanyLower TargetOverweight ➝ Overweight$145.00 ➝ $80.00
7/26/2024Robert W. BairdDowngradeOutperform ➝ Neutral$161.00 ➝ $80.00
7/26/2024JPMorgan Chase & Co.DowngradeOverweight ➝ Neutral$145.00 ➝ $75.00
7/23/2024Canaccord Genuity GroupReiterated RatingBuy ➝ Buy$145.00 ➝ $145.00
7/15/2024Morgan StanleyLower TargetEqual Weight ➝ Equal Weight$132.00 ➝ $120.00
7/12/2024Stifel NicolausLower TargetBuy ➝ Buy$145.00 ➝ $132.00
5/30/2024Redburn AtlanticInitiated CoverageNeutral$130.00
4/26/2024Raymond JamesBoost TargetStrong-Buy ➝ Strong-Buy$151.00 ➝ $160.00
4/26/2024Canaccord Genuity GroupBoost TargetBuy ➝ Buy$144.00 ➝ $145.00
4/10/2024UBS GroupBoost TargetBuy ➝ Buy$153.00 ➝ $163.00
4/3/2024CitigroupBoost TargetBuy ➝ Buy$148.00 ➝ $161.00
3/12/2024Royal Bank of CanadaInitiated CoverageOutperform$165.00
1/23/2024Raymond JamesBoost TargetStrong-Buy ➝ Strong-Buy$147.00 ➝ $151.00
1/3/2024Raymond JamesBoost TargetStrong-Buy ➝ Strong-Buy$131.00 ➝ $147.00
12/19/2023Piper SandlerBoost TargetOverweight ➝ Overweight$135.00 ➝ $150.00
12/13/2023Wells Fargo & CompanyBoost TargetOverweight ➝ Overweight$110.00 ➝ $136.00
12/4/2023Morgan StanleyBoost TargetEqual Weight ➝ Equal Weight$101.00 ➝ $122.00
10/27/2023Morgan StanleyBoost TargetEqual Weight ➝ Equal Weight$98.00 ➝ $101.00
10/17/2023JPMorgan Chase & Co.Lower TargetOverweight ➝ Overweight$160.00 ➝ $100.00
10/16/2023Leerink PartnrsReiterated RatingOutperform
10/16/2023Leerink PartnersInitiated CoverageOutperform$110.00
10/10/2023Stifel NicolausLower TargetBuy ➝ Buy$155.00 ➝ $145.00
10/2/2023CitigroupLower Target$150.00 ➝ $115.00
9/29/2023Morgan StanleyLower TargetEqual Weight ➝ Equal Weight$131.00 ➝ $98.00
9/15/2023Raymond JamesLower TargetStrong-Buy ➝ Strong-Buy$154.00 ➝ $131.00
9/6/2023UBS GroupLower TargetBuy ➝ Buy$175.00 ➝ $138.00
8/21/2023Robert W. BairdLower TargetOutperform ➝ Outperform$153.00 ➝ $130.00
7/31/2023BarclaysBoost TargetEqual Weight$115.00 ➝ $138.00
7/28/2023Canaccord Genuity GroupBoost TargetBuy$135.00 ➝ $150.00
7/28/2023Raymond JamesBoost Target$140.00 ➝ $154.00
7/28/2023Piper SandlerBoost TargetOverweight$150.00 ➝ $160.00
7/28/2023OppenheimerBoost Target$135.00 ➝ $150.00
7/28/2023Robert W. BairdBoost Target$145.00 ➝ $153.00
7/10/2023CitigroupBoost Target$146.00 ➝ $150.00
6/26/2023BTIG ResearchBoost Target$134.00 ➝ $150.00
5/30/2023Morgan StanleyInitiated CoverageEqual Weight$131.00
5/1/2023BarclaysBoost Target$110.00 ➝ $115.00
4/28/2023Stifel NicolausBoost Target$130.00 ➝ $140.00
4/28/2023UBS GroupBoost Target$142.00 ➝ $150.00
4/28/2023BTIG ResearchBoost Target$132.00 ➝ $134.00
4/28/2023Raymond JamesBoost Target$138.00 ➝ $140.00
4/17/2023BTIG ResearchBoost TargetBuy$126.00 ➝ $132.00
4/17/2023Raymond JamesUpgradeOutperform ➝ Strong-Buy$127.00 ➝ $138.00
3/28/2023UBS GroupInitiated CoverageBuy$142.00
2/13/2023BarclaysBoost TargetEqual Weight$103.00 ➝ $110.00
2/10/2023CowenBoost TargetOutperform$114.00 ➝ $125.00
1/26/2023Wolfe ResearchInitiated CoverageOutperform$121.00
1/6/2023Morgan StanleyBoost TargetEqual Weight$117.00 ➝ $131.00
12/20/2022Stifel NicolausBoost Target$120.00 ➝ $130.00
12/12/2022CitigroupBoost TargetBuy$117.00 ➝ $146.00
11/1/2022Piper SandlerBoost Target$130.00
11/1/2022BTIG ResearchBoost Target$126.00
10/28/2022Raymond JamesBoost TargetOutperform$101.00 ➝ $125.00
10/28/2022Morgan StanleyBoost TargetEqual Weight$107.00 ➝ $117.00
10/28/2022Wells Fargo & CompanyBoost TargetOverweight$102.00 ➝ $128.00
10/28/2022CowenBoost Target$85.00 ➝ $114.00
10/28/2022CowenBoost Target$85.00 ➝ $114.00
10/28/2022CitigroupBoost Target$105.00 ➝ $117.00
10/28/2022Robert W. BairdBoost Target$97.00 ➝ $120.00
10/17/2022BarclaysInitiated CoverageEqual Weight$103.00
10/12/2022Jefferies Financial GroupInitiated CoverageBuy$125.00
10/11/2022Morgan StanleyBoost TargetEqual Weight$83.00 ➝ $107.00
10/10/2022BTIG ResearchBoost TargetBuy$92.00 ➝ $110.00
10/7/2022Piper SandlerBoost TargetOverweight$110.00 ➝ $120.00
10/7/2022Stifel NicolausBoost TargetBuy$112.00 ➝ $120.00
7/29/2022CowenReiterated RatingBuy$85.00
7/29/2022OppenheimerLower Target$131.00 ➝ $105.00
7/29/2022Wells Fargo & CompanyLower Target$144.00 ➝ $102.00
7/29/2022Piper SandlerLower TargetOverweight$120.00 ➝ $110.00
7/29/2022Morgan StanleyLower TargetEqual Weight$91.00 ➝ $83.00
7/29/2022Robert W. BairdLower Target$115.00 ➝ $97.00
7/29/2022CitigroupLower Target$105.00 ➝ $100.00
7/15/2022Sanford C. BernsteinInitiated CoverageOutperform$105.00
6/24/2022BTIG ResearchLower TargetBuy$135.00 ➝ $105.00
6/13/2022Morgan StanleyLower TargetEqual Weight$90.75
6/7/2022Morgan StanleyLower TargetEqual Weight$123.00 ➝ $90.75
5/17/2022CitigroupLower TargetBuy$157.50 ➝ $131.25
4/29/2022Leerink PartnersLower Target$141.25 ➝ $125.00
4/29/2022Canaccord Genuity GroupLower Target$131.25 ➝ $125.00
4/29/2022Raymond JamesLower Target$134.50 ➝ $121.50
4/29/2022Piper SandlerLower Target$181.25 ➝ $120.00
4/18/2022BTIG ResearchBoost Target$133.75 ➝ $140.00
3/2/2022Bank of AmericaInitiated CoverageBuy ➝ Buy
2/11/2022Robert W. BairdLower Target$156.25 ➝ $140.00
2/11/2022Morgan StanleyLower TargetEqual Weight$142.50 ➝ $128.50
2/11/2022CitigroupLower Target$165.00 ➝ $157.50
2/3/2022BTIG ResearchUpgradeNeutral ➝ Buy$133.75
1/19/2022Raymond JamesLower TargetOutperform$154.50 ➝ $134.50
1/19/2022Wells Fargo & CompanyUpgradeEqual Weight ➝ Overweight$143.75
1/7/2022Morgan StanleyLower TargetEqual Weight$144.00 ➝ $142.50
1/7/2022GuggenheimUpgradeNeutral ➝ Buy$145.00
11/1/2021Raymond JamesBoost TargetOutperform$128.75 ➝ $154.50
10/29/2021Jefferies Financial GroupBoost TargetBuy$152.50 ➝ $163.75
10/29/2021OppenheimerBoost TargetOutperform$131.25 ➝ $156.25
10/29/2021Leerink PartnersBoost TargetOutperform$125.00 ➝ $178.75
10/29/2021Morgan StanleyBoost TargetEqual Weight$127.50 ➝ $144.00
10/29/2021CitigroupBoost TargetBuy$157.50 ➝ $165.00
10/29/2021Robert W. BairdBoost TargetOutperform$130.00 ➝ $156.25
10/29/2021Piper SandlerBoost TargetOverweight$162.50 ➝ $168.75
10/18/2021GuggenheimDowngradeBuy ➝ Neutral
10/1/2021CitigroupBoost TargetBuy$132.50 ➝ $157.50
9/16/2021Piper SandlerBoost TargetOverweight$137.50 ➝ $162.50
8/2/2021Morgan StanleyBoost TargetEqual Weight$102.50 ➝ $127.50
7/30/2021StephensBoost TargetOverweight$117.00 ➝ $136.50
7/30/2021Wells Fargo & CompanyBoost TargetEqual Weight$95.00 ➝ $118.75
7/30/2021Leerink PartnersBoost TargetOutperform$121.25 ➝ $125.00
7/30/2021OppenheimerBoost TargetOutperform$125.00 ➝ $131.25
7/30/2021Raymond JamesBoost TargetOutperform$116.50 ➝ $128.75
7/30/2021Robert W. BairdBoost TargetOutperform$115.00 ➝ $130.00
7/30/2021Piper SandlerBoost TargetOverweight$125.00 ➝ $137.50
7/21/2021CowenLower TargetOutperform$135.00 ➝ $131.25
7/1/2021StephensReiterated RatingBuy$117.00
5/28/2021Wells Fargo & CompanyUpgradeUnderweight ➝ Equal Weight$95.00
5/24/2021BarclaysInitiated CoverageOverweight$125.00
4/30/2021CitigroupBoost Target$120.00 ➝ $122.00
4/30/2021Raymond JamesBoost TargetOutperform$112.25 ➝ $116.50
4/15/2021Atlantic SecuritiesInitiated CoverageOverweight$109.50
2/12/2021CitigroupLower TargetBuy$121.25 ➝ $120.00
2/12/2021OppenheimerBoost TargetOutperform$103.75 ➝ $112.25
2/12/2021Morgan StanleyBoost TargetEqual Weight$100.50 ➝ $102.50
2/12/2021Raymond JamesBoost TargetOutperform$103.75 ➝ $112.25
1/29/2021Piper SandlerBoost TargetOverweight$116.25 ➝ $125.00
1/6/2021UBS GroupUpgradeNeutral ➝ Buy$102.50 ➝ $111.25
12/15/2020Morgan StanleyBoost TargetEqual Weight$99.50 ➝ $100.50
12/10/2020Raymond JamesReiterated RatingBuy
11/20/2020Piper SandlerReiterated RatingBuy$116.25
10/28/2020Stifel NicolausLower TargetBuy$125.00 ➝ $118.75
10/28/2020Raymond JamesLower TargetOutperform$112.50 ➝ $109.50
10/28/2020Morgan StanleyLower TargetEqual Weight$107.00 ➝ $99.50
10/2/2020Wells Fargo & CompanyDowngradeEqual Weight ➝ Underweight$105.00 ➝ $87.50
7/29/2020UBS GroupBoost TargetNeutral$83.75 ➝ $100.00
7/29/2020Morgan StanleyBoost TargetEqual Weight$94.25 ➝ $107.00
7/29/2020Raymond JamesBoost TargetOutperform$98.75 ➝ $112.50
7/29/2020Stifel NicolausBoost TargetBuy$96.25 ➝ $125.00
7/29/2020Leerink PartnersBoost TargetEqual Weight ➝ Outperform$116.25 ➝ $121.25
7/29/2020CitigroupBoost TargetBuy$110.00 ➝ $121.25
7/29/2020Piper SandlerBoost TargetOverweight$112.50 ➝ $116.25
7/28/2020OppenheimerInitiated CoverageBuy$90.00 ➝ $111.25
7/28/2020Bank of AmericaReiterated RatingBuy$125.00
7/27/2020JPMorgan Chase & Co.Boost TargetOverweight$90.00 ➝ $112.50
7/7/2020CowenBoost TargetPositive ➝ Outperform$107.50 ➝ $112.50
6/17/2020Bank of AmericaBoost TargetBuy$93.75 ➝ $125.00
6/9/2020Raymond JamesBoost TargetOutperform$90.00 ➝ $98.75
6/3/2020CitigroupBoost TargetAverage ➝ Buy$90.25 ➝ $110.00
5/27/2020Piper SandlerBoost TargetOverweight$93.75 ➝ $112.50
(Data available from 5/21/2020 forward)

News Sentiment Rating

1.33 (Buy)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 33 very positive mentions
  • 114 positive mentions
  • 8 negative mentions
  • 4 very negative mentions
Mentions as of
10/23/2024
  • 50 very positive mentions
  • 26 positive mentions
  • 6 negative mentions
  • 1 very negative mentions
Mentions as of
11/22/2024
  • 74 very positive mentions
  • 28 positive mentions
  • 0 negative mentions
  • 1 very negative mentions
Mentions as of
12/22/2024
  • 31 very positive mentions
  • 26 positive mentions
  • 2 negative mentions
  • 0 very negative mentions
Mentions as of
1/21/2025
  • 80 very positive mentions
  • 32 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
Mentions as of
2/20/2025
  • 79 very positive mentions
  • 13 positive mentions
  • 8 negative mentions
  • 3 very negative mentions
Mentions as of
3/22/2025
  • 99 very positive mentions
  • 33 positive mentions
  • 1 negative mentions
  • 2 very negative mentions
Mentions as of
4/21/2025
  • 109 very positive mentions
  • 28 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
Mentions as of
5/21/2025

Current Sentiment

  • 109 very positive mentions
  • 28 positive mentions
  • 1 negative mentions
  • 0 very negative mentions

Recent Stories by Sentiment

Very Negative

  • No very negative mentions tracked during this time.

Negative

Positive

Very Positive

DexCom logo
DexCom, Inc., a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include Dexcom G6 and Dexcom G7, integrated CGM systems for diabetes management; Dexcom Share, a remote monitoring system; Dexcom Real-Time API, which enables authorized third-party software developers to integrate real-time CGM data into their digital health apps and devices; and Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions. It has also submitted FDA review for Dexcom Stelo for people with type 2 diabetes. The company has a collaboration and license agreement with Verily Life Sciences LLC and Verily Ireland Limited to develop blood-based or interstitial glucose monitoring products. It markets its products directly to endocrinologists, physicians, and diabetes educators. The company was incorporated in 1999 and is headquartered in San Diego, California.
Read More

Today's Range

Now: $85.65
Low: $85.60
High: $87.00

50 Day Range

MA: $72.71
Low: $59.83
High: $87.34

52 Week Range

Now: $85.65
Low: $57.52
High: $131.76

Volume

379,376 shs

Average Volume

4,343,528 shs

Market Capitalization

$33.58 billion

P/E Ratio

59.88

Dividend Yield

N/A

Beta

1.43

Frequently Asked Questions

What sell-side analysts currently cover shares of DexCom?

The following equities research analysts have issued research reports on DexCom in the last year: Baird R W, Barclays PLC, BTIG Research, Canaccord Genuity Group Inc., Cfra Research, Citigroup Inc., JPMorgan Chase & Co., Leerink Partners, Mizuho, Morgan Stanley, Oppenheimer Holdings Inc., Piper Sandler, Raymond James, Redburn Atlantic, Robert W. Baird, Royal Bank of Canada, Sanford C. Bernstein, Stifel Nicolaus, StockNews.com, UBS Group AG, and Wells Fargo & Company.
View the latest analyst ratings for DXCM.

What is the current price target for DexCom?

0 Wall Street analysts have set twelve-month price targets for DexCom in the last year. Their average twelve-month price target is $98.11, suggesting a possible upside of 12.3%. BTIG Research has the highest price target set, predicting DXCM will reach $120.00 in the next twelve months. Morgan Stanley has the lowest price target set, forecasting a price of $82.00 for DexCom in the next year.
View the latest price targets for DXCM.

What is the current consensus analyst rating for DexCom?

DexCom currently has 4 hold ratings, 13 buy ratings and 3 strong buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Moderate Buy."
View the latest ratings for DXCM.

What other companies compete with DexCom?

Other companies that are similar to DexCom include Medtronic, Becton, Dickinson and Company, Edwards Lifesciences, IDEXX Laboratories and ResMed. Learn More about companies similar to DexCom.

How do I contact DexCom's investor relations team?

DexCom's physical mailing address is 6340 SEQUENCE DRIVE, SAN DIEGO CA, 92121. The medical device company's listed phone number is (858) 200-0200 and its investor relations email address is [email protected]. The official website for DexCom is www.dexcom.com. Learn More about contacing DexCom investor relations.